| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA666393 | F | Inhibitory concentration required to reduce viral plaque formation of Coxsackie B5 virus by 50% | Coxsackievirus B5 | 3 | ALA1132137 | organism-based format | Scientific Literature | |
| 2. | ALA664048 | F | Antiviral activity against the Coxsackie B5 virus (RNA virus) at a concentration of 5 ug/mL was determined as total cell infectious dose 50/mL (TCID50) by viral yield assay | Coxsackievirus B5 | 2 | ALA1132137 | organism-based format | Scientific Literature | |
| 3. | ALA691151 | F | Minimum cytotoxic concentration against HEL cell morphology. | Homo sapiens | 16 | ALA1135344 | cell-based format | Scientific Literature | |
| 4. | ALA690151 | F | Cytotoxic concentration reducing HEL cell growth by 50%. | Homo sapiens | 16 | ALA1135344 | cell-based format | Scientific Literature | |
| 5. | ALA694176 | F | Antiviral activity against the Herpes simplex 1 virus (DNA virus) at a concentration of 5 ug/mL was determined as Plaque forming unit/mL(PFU) by plaque assay; ND-Not determined | Human alphaherpesvirus 1 | 1 | ALA1132137 | organism-based format | Scientific Literature | |
| 6. | ALA696951 | F | Antiviral activity was tested against human cytomegalovirus AD-169 which reduces virus plaque formation by 50% | Human betaherpesvirus 5 | 14 | ALA1135344 | organism-based format | Scientific Literature | |
| 7. | ALA696953 | F | Antiviral activity was tested against human cytomegalovirus Davis which reduces virus plaque formation by 50% | Human betaherpesvirus 5 | 14 | ALA1135344 | organism-based format | Scientific Literature | |
| 8. | ALA746206 | F | Antiviral activity against the Mumps virus (RNA virus) at a concentration of 5 ug/mL was determined as total cell infectious dose 50/mL (TCID50) by viral yield assay; ND-Not determined | Mumps orthorubulavirus | 1 | ALA1132137 | organism-based format | Scientific Literature | |
| 9. | ALA746237 | F | Antiproliferative activity was tested against murine leukemia cells-L1210/0 | Mus musculus | 12 | ALA1135344 | cell-based format | Scientific Literature | |
| 10. | ALA812947 | F | Antiproliferative activity was tested against human T-lymphocyte cells-CEM/0 | Homo sapiens | 11 | ALA1135344 | cell-based format | Scientific Literature | |
| 11. | ALA812948 | F | Antiproliferative activity was tested against human T-lymphocyte cells-Molt 4/C8 | Homo sapiens | 12 | ALA1135344 | cell-based format | Scientific Literature | |
| 12. | ALA818213 | F | Antiviral activity was tested against TK- Varicella-Zoster virus 07/1 which reduces virus plaque formation by 50% | Human alphaherpesvirus 3 | 14 | ALA1135344 | organism-based format | Scientific Literature | |
| 13. | ALA818214 | F | Antiviral activity was tested against TK+ Varicella-Zoster virus OKA which reduces virus plaque formation by 50% | Human alphaherpesvirus 3 | 14 | ALA1135344 | organism-based format | Scientific Literature | |
| 14. | ALA818216 | F | Antiviral activity was tested against TK+ Varicella-Zoster virus YS which reduces virus plaque formation by 50% | Human alphaherpesvirus 3 | 14 | ALA1135344 | organism-based format | Scientific Literature | |
| 15. | ALA818220 | F | Antiviral activity was tested against TK- Varicella-Zoster virus YS/R which reduces virus plaque formation by 50% | Human alphaherpesvirus 3 | 14 | ALA1135344 | organism-based format | Scientific Literature | |
| 16. | ALA823646 | F | Antiviral activity against the Vaccinia virus (DNA virus) at a concentration of 5 ug/mL was determined as Plaque forming unit/mL(PFU) by plaque assay; ND-Not determined | Vaccinia virus | 1 | ALA1132137 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!